{"id":132,"date":"2023-07-24T12:16:00","date_gmt":"2023-07-24T10:16:00","guid":{"rendered":"https:\/\/aplusa.local\/?p=132"},"modified":"2026-02-03T17:17:59","modified_gmt":"2026-02-03T16:17:59","slug":"smml-6-asco-eha-2023-post-congress-focus","status":"publish","type":"post","link":"https:\/\/www.aplusaresearch.com\/fr\/perspectives\/smml-6-asco-eha-2023-post-congress-focus\/","title":{"rendered":"SMML #6 ASCO &amp; EHA 2023 : Focus post-congr\u00e8s"},"content":{"rendered":"<p>L'objectif de cette lettre d'information est de donner un aper\u00e7u de ce qui se passe autour du my\u00e9lome multiple en termes de d\u00e9veloppements m\u00e9dicaux. Pour ce faire, nous suivons d'une part les articles de presse, les communiqu\u00e9s de presse et les rapports scientifiques. D'autre part, les conversations des professionnels de la sant\u00e9, des leaders d'opinion num\u00e9riques et d'autres influenceurs qui assistent aux congr\u00e8s, donnent leur avis sur les traitements et commentent les nouveaux d\u00e9veloppements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Objectifs<\/h2>\n\n\n\n<p>Qui b\u00e9n\u00e9ficiera de cette lettre d'information ?<\/p>\n\n\n\n<p>Tous les professionnels souhaitant se tenir au courant des d\u00e9veloppements concernant le my\u00e9lome multiple :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Les sp\u00e9cialistes du marketing<\/li>\n\n\n\n<li>Analystes d'entreprise<\/li>\n\n\n\n<li>Mais aussi les professionnels de la sant\u00e9 qui souhaitent anticiper le paysage futur de la prise en charge du MM.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Champ d'application<\/h2>\n\n\n\n<p>L'analyse porte sur les mentions provenant du monde entier*.<\/p>\n\n\n\n<p>Il y a eu un total de 30K mentions de patients enregistr\u00e9es pendant la p\u00e9riode d'\u00e9coute du 1er juin 2023 au 30 juin 2023.<\/p>\n\n\n\n<p>La majorit\u00e9 des mentions proviennent de News (46%), Twitter (42%), Tumblr (7%), Forums (2%), Reddit (1%), Blogs (1%) et Instagram (1%).<\/p>\n\n\n\n<p>Au total, 8 000 auteurs uniques ont \u00e9t\u00e9 identifi\u00e9s.<\/p>\n\n\n\n<p class=\"is-style-text-annotation\">: My\u00e9lome OR multiplemyeloma OR #Mmsm OR #Myeloma OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title : (\"multiple myeloma\" OR myeloma)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">M\u00e9thodologie<\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"960\" height=\"540\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/promo-smml-newsletter.webp\" class=\"wp-image-337\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/promo-smml-newsletter.webp 960w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/promo-smml-newsletter-300x169.webp 300w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/promo-smml-newsletter-768x432.webp 768w\" sizes=\"auto, (max-width: 960px) 100vw, 960px\" \/><\/figure>\n\n\n\n<p>Les discussions autour de #ASCO23 ont occup\u00e9 le devant de la sc\u00e8ne ce mois-ci, le cilta-cel CAR-T \u00e9tant le m\u00e9dicament le plus mentionn\u00e9 par les professionnels de la sant\u00e9.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Partage de la voix : sujets de conversation<\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"882\" height=\"425\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-41-23-4803-am.png\" class=\"wp-image-338\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-41-23-4803-am.png 882w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-41-23-4803-am-300x145.avif 300w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-41-23-4803-am-768x370.avif 768w\" sizes=\"auto, (max-width: 882px) 100vw, 882px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Partage de la voix : Mol\u00e9cules<\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"869\" height=\"450\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-05-4741-am.avif\" class=\"wp-image-339\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-05-4741-am.avif 869w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-05-4741-am-300x155.avif 300w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-05-4741-am-768x398.avif 768w\" sizes=\"auto, (max-width: 869px) 100vw, 869px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"451\" height=\"321\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-14-3375-am.webp\" class=\"wp-image-341\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-14-3375-am.webp 451w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-42-14-3375-am-300x214.webp 300w\" sizes=\"auto, (max-width: 451px) 100vw, 451px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">L'ASCO23 se concentre sur le my\u00e9lome multiple<\/h2>\n\n\n\n<p>L'\u00e9dition de cette ann\u00e9e \u00e9tait fortement ax\u00e9e sur les th\u00e9rapies cellulaires CAR-T et les anticorps bisp\u00e9cifiques.<\/p>\n\n\n\n<p>Les r\u00e9sultats tr\u00e8s attendus de l'essai CARTITUDE-4 en t\u00e9moignent. D'autres d\u00e9veloppements \u00e0 noter sont le teclistamab et le talquetamab et les essais correspondants RedirecTT-1 et MajesTEC-1.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Sujets de discussion (type de traitement)<\/h3>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"447\" height=\"223\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-43-55-8347-am.webp\" class=\"wp-image-342\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-43-55-8347-am.webp 447w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-43-55-8347-am-300x150.webp 300w\" sizes=\"auto, (max-width: 447px) 100vw, 447px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"511\" height=\"224\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-47-10-0833-am.webp\" class=\"wp-image-343\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-47-10-0833-am.webp 511w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-47-10-0833-am-300x132.webp 300w\" sizes=\"auto, (max-width: 511px) 100vw, 511px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Essais cliniques les plus mentionn\u00e9s<\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"645\" height=\"291\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-45-47-7315-am.avif\" class=\"wp-image-344\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-45-47-7315-am.avif 645w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-45-47-7315-am-300x135.avif 300w\" sizes=\"auto, (max-width: 645px) 100vw, 645px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Mol\u00e9cules les plus cit\u00e9es<\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"750\" height=\"220\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-46-55-5247-am.avif\" class=\"wp-image-345\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-46-55-5247-am.avif 750w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-46-55-5247-am-300x88.avif 300w\" sizes=\"auto, (max-width: 750px) 100vw, 750px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">#EHA23 Focus sur le my\u00e9lome multiple<\/h2>\n\n\n\n<p>Globalement, les anticorps bisp\u00e9cifiques elranatamab et talquetamab ont occup\u00e9 le devant de la sc\u00e8ne en ligne au cours du #eha23, les r\u00e9sultats de MagnetisMM-3 \u00e9tant particuli\u00e8rement cit\u00e9s.<\/p>\n\n\n\n<p>Influenc\u00e9es par les r\u00e9sultats de CARTITUTE-4 et les r\u00e9sultats suppl\u00e9mentaires de CARTITUDE-1, les th\u00e9rapies CAR-T ont \u00e9galement suscit\u00e9 un vif int\u00e9r\u00eat, le cilta-cel \u00e9tant la mol\u00e9cule la plus mentionn\u00e9e.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Sujets de discussion (type de traitement)<\/h3>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"469\" height=\"234\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-49-12-5944-am.webp\" class=\"wp-image-346\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-49-12-5944-am.webp 469w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-49-12-5944-am-300x150.webp 300w\" sizes=\"auto, (max-width: 469px) 100vw, 469px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"488\" height=\"219\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-49-38-1083-am.webp\" class=\"wp-image-347\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-49-38-1083-am.webp 488w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-49-38-1083-am-300x135.webp 300w\" sizes=\"auto, (max-width: 488px) 100vw, 488px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Essais cliniques les plus mentionn\u00e9s<\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"707\" height=\"326\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-50-31-9463-am.avif\" class=\"wp-image-348\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-50-31-9463-am.avif 707w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-50-31-9463-am-300x138.avif 300w\" sizes=\"auto, (max-width: 707px) 100vw, 707px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Mol\u00e9cules les plus cit\u00e9es<\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><img alt=\"\" loading=\"lazy\" decoding=\"async\" width=\"879\" height=\"209\" src=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-51-15-4863-am.avif\" class=\"wp-image-349\" srcset=\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-51-15-4863-am.avif 879w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-51-15-4863-am-300x71.avif 300w, https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2023\/07\/image-png-jul-24-2023-09-51-15-4863-am-768x183.avif 768w\" sizes=\"auto, (max-width: 879px) 100vw, 879px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">De retour d'EHA 2023 - APLUSA et le Dr. BLIN ont pr\u00e9sent\u00e9 le poster MM pendant le congr\u00e8s<\/h2>\n\n\n\n<p>Le Dr Nicolas BLIN, h\u00e9matologue au CHU de Nantes, a accompagn\u00e9 nos experts et a eu l'occasion de pr\u00e9senter le poster :<\/p>\n\n\n\n<p>UTILISATION R\u00c9ELLE DES TRAITEMENTS SYST\u00c9MIQUES ACTUELS ET INFLUENCE DES FACTEURS CL\u00c9S POUR LE MY\u00c9LOME MULTIPLE DANS LES DEUX PREMI\u00c8RES LIGNES DE TRAITEMENT. DONN\u00c9ES ISSUES D'UNE \u00c9TUDE EN SITUATION R\u00c9ELLE DANS LES PAYS DE L'UE5<\/p>\n\n\n\n<p>qu'il a co-cr\u00e9\u00e9 avec nos experts APLUSA Melissa YILMAZ et Siegfried ERTL.<\/p>\n\n\n\n<p>Vous pouvez t\u00e9l\u00e9charger et acc\u00e9der \u00e0 l'affiche en cliquant sur le bouton ci-dessous.<\/p>\n\n\n\n<p>Lors de la s\u00e9ance de posters du vendredi soir, le Dr. BLIN a pr\u00e9sent\u00e9 les r\u00e9sultats dans une vid\u00e9o d\u00e9taill\u00e9e. Acc\u00e9dez \u00e0 la vid\u00e9o en cliquant sur le bouton ci-dessous et apprenez-en plus sur nos donn\u00e9es MM issues d'une \u00e9tude en conditions r\u00e9elles :<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" hcb-fetch-image-from=\"https:\/\/www.youtube.com\/watch?v=yUmrkyD1gvc\" title=\"APLUSA et le Dr Nicolas BLIN pr\u00e9sentent un poster sur le my\u00e9lome multiple lors de l&#039;EHA 2023 \u00e0 Francfort\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/yUmrkyD1gvc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>Apr\u00e8s le congr\u00e8s, nous avons organis\u00e9 un webinaire en direct avec le Dr. Nicolas BLIN qui a mis en lumi\u00e8re les moments cl\u00e9s de l'EHA.<\/p>\n\n\n\n<p>Co-mod\u00e9r\u00e9 par nos experts Melissa YILMAZ et Siegfried ERTL, le Dr. BLIN a pr\u00e9sent\u00e9 les derni\u00e8res actualit\u00e9s en h\u00e9matologie, comment\u00e9 quelques abstracts bas\u00e9s sur des essais cliniques en cours et partag\u00e9 ses r\u00e9flexions sur diff\u00e9rents sujets d'actualit\u00e9 en h\u00e9matologie (my\u00e9lome multiple, leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb, my\u00e9lofibrose, anticorps bisp\u00e9cifiques, th\u00e9rapies CAR T cell, etc.)<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" hcb-fetch-image-from=\"https:\/\/www.youtube.com\/watch?v=Nyz9b6v2hJM\" title=\"Replay - De retour du congr\u00e8s : Les temps forts de l&#039;EHA avec le Dr.\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/Nyz9b6v2hJM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7076,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"Stay ahead in multiple myeloma with global insights on CAR-T, bispecific antibodies, ASCO & EHA highlights, trials, and expert HCP commentary.","_seopress_robots_index":"","content-type":"","footnotes":""},"categories":[80],"tags":[],"class_list":{"0":"post-132","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-views"},"acf":[],"_links":{"self":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/comments?post=132"}],"version-history":[{"count":0,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/132\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/media\/7076"}],"wp:attachment":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/media?parent=132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/categories?post=132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/tags?post=132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}